MELA Sciences to Release Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on Tuesday, March 5, 2013

MELA Sciences to Release Fourth Quarter and Year End 2012 Financial Results
and Host Conference Call on Tuesday, March 5, 2013

IRVINGTON, N.Y., Feb. 4, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind^®, today announced that it will release its 2012
fourth quarter and year-end financial results after the close of trading on
Tuesday, March 5, 2013. MELA Sciences executives will also host a conference
call that day at 4:30 PM ET to discuss the results, as well as provide a
general business update.

Date: Tuesday, March 5, 2013
Time:  4:30 PM ET

To participate in the teleconference, please dial:
Domestic toll-free:         (877) 303-9205
International:              (760) 536-5226
Participant Code:           95085190

To listen via live webcast, please go to the investor relations section of the
MELA Sciences website at http://www.melasciences.com approximately 10 minutes
prior to the teleconference start time. If you are unable to participate
during the live conference call and webcast, the conference call webcast will
be archived and available for replay for approximately 90 days.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind^®, and its further design and development.
MelaFind is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

CONTACT: For Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         For Media
         Erica Sperling
         Rpr Marketing Communications
         212.317.1462
         erica.sperling@rprmc.com